摘要
On a hot morning in July 2020,Liang Hongyang,deputy director of the No.6 Vaccine Office of the Beijing Institute of Biological Products(BJIBP)under China National Biotec Group(CNBG),a subsidiary of China National Pharmaceutical Group(Sinopharm),rushed into the lab working on the COVID-19 vaccine.When he left the BJIBP building,Liang saw tents were pitched and people were waiting in a long queue to get vaccinated.He overheard someone say,“I finally feel safe after getting vaccinated.”Liang felt quite relieved to hear that.He has been a core member of the R&D team for the COVID-19 vaccine since the beginning of 2020.The development and successful trials of the vaccine could only happen thanks to the hard work of the whole team.
